SANDOZ
PHARMACEUTICALS

DIVISION OF INC.
HANOVER, NEW JERSEY

August 13, 1957

(3) (117)

See Aufzeichnung

Harris Isbell, M.D.
National Institute of Mental Health
Addiction Center
U. S. Public Health Service Hospital
P.O. Box 2000
Lexington, Kentucky

Dear Doctor Isbell:

Late, but I hope not too late, I would like to thank you most sincerely for your splendid hospitality and the most interesting and stimulating discussion of our mutual problems.

I have just received a list from Basel which shows some new compounds which are available to you. Would you be kind enough to let us know which ones you would like to screen. I am sure that Basel will send us also acute toxicity data, which would enable you to get some ideas about their doses in humans. The different code numbers BMI 61, MLA 74, MLA 10, MLD 75 stand for the following chemical names:

BMI 61 - l-methyl-2-brom-lysergic acid diethylamide

MLA 74 - l-methyl-lysergic acid monoethylamide

MLA 10 - l-methyl-lysergic acid-monoethylamide

MLD 75 - l-methyl-lysergic acid pyrrolidide.

Enclosed I am sending you also pharmacological data on three phenethylamine derivatives, i.e. UM 75, UM 71 and UM 11. We could furnish you with tablets containing 25 and 50 mg. of active ingredients as well as placebos if you [illegible]

Furthermore, I am sending you herewith an expose regarding UM 1-30. We talked about this compound briefly in Chicago as well as in Lexington. We would appreciate it very much if you could include this compound in your screening program, since we also can weather in addition to amphetamine effects it also possesses psychotomimetic properties. I could send you 5 mg. tablets as well as pure substance.

For all the [illegible] I am thanking you [illegible] for the materials you would [illegible]

Yours [illegible]

SANDOZ PHARMA

PAGE NO. 2

I have just read with great interest an article which deals with the abuse of analgesics in Switzerland and which appeared in the Schweizerische Aerztezeitung 38:307 (July 5) 1957 "Erhebung ueber Anamnese, Verbreitung und Prophylaxe des Medikamentab-, Insbesondere des analgetikamissbrauchs in der Schweiz". I thought that you, too, would be interested in this subject and, therefore, I am sending you herewith a verifax copy of the article.*

Just in case you have in mind to go to Switzerland, I am sending you a small booklet in English which briefly describes Switzerland from different aspects.

I enclose also our newsletter Bright Futures Booklet which I thought might be of interest to you and which you might like to have for your files.

I would be in a position to prepare an exposé dealing with the adrenergic blocking effects of ergot alkaloids in animals and humans. Would you please let me know whether you would like to have it?

I hope that I [illegible]

I wrote to [illegible] analogues available, especially analogues with changes in position 1 and/or 2 in the lysergic acid nucleus.

The only wish I have is to have the opportunity to see you soon again, and in the meantime, I am, with my very best regards,

Yours grateful,

R. Dirscherl, M.D.
Medical Director.

*) under separate cover.

A-406



MBL 61

530



MLA 74

830

LAE- deriv.

(LAE antiserc
index= 11-12



ALA 10

40

A-405

Copied: Basle Zurich



Fn. Lab.
No. 5794

Pharmacological [illegible]
are yet available



No. 8154



No. 8157

Copies: Stable [illegible]